Recent Scientific Publications

Venn’s Medical and Methodology Team will continue to manage its commitment of working collaboratively with our clients and building on its past successes throughout 2020 (https://www.vennlifesciences.com/methodology-study-design-biostatistics-consulting/). As 2019 draws to a close, we are looking back at two recent scientific publications co-authored with a client, involving two members of our Medical and Methodology team.

Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with poor prognosis.

Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with poor prognosis. The Venn Team partnered with one of our clients for a Phase 2 (117 patients, 18 sites, 7 countries), randomized, 28 weeks double-blind, placebo-controlled trial to determine the effect of recombinant human pentraxin 2 vs. placebo in patient with IPF. The randomized part of the study was followed by a long term open-label extension, were all patients received the active treatment.
The results of the 28 weeks randomized double blind placebo-controlled part of the study were published in the Journal of the American Medical Association (JAMA) in 2018: Raghu et al, Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis A Randomized Clinical Trial, JAMA. 2018;319(22):2299-2307: https://jamanetwork.com/journals/jama/article-abstract/2681945?widget=personalizedcontent&previousarticle=2681942) and is co-authored by one of our Venn’s Biometrics and Methodology Consultant, Hugues Santin-Janin.

The long-term open-label extension interim results were then published in The Lancet Respiratory Medicine in 2019, with Hugues Santin-Janin and Francois Aubin as co-authors: Raghu et al, Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study, The Lancet Respiratory Medicine 2019, 7, (8): 657-664: http://dx.doi.org/10.1016/S2213-2600(19)30172-9).